On August 30, 2018 Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, reported that new proof-of-concept preliminary data from its ongoing China clinical study evaluating ET140202 for the treatment of AFP-positive hepatocellular carcinoma (AFP+ HCC) will be presented as a late-breaking oral presentation at the 4th Annual CAR-TCR Summit in Boston, Massachusetts, September 4-7, 2018 (Press release, Eureka Therapeutics, AUG 30, 2018, View Source [SID1234529199]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation details are listed below and are accessible on the 4th Annual CAR-TCR Summit website:

Presentation Title: Case Report of Regression of Metastatic Liver Cancer After ET140202 T-Cell Therapy
Session Title: Late Breaking Abstracts
Date & Time: Wednesday, September 5, 2018 from 9:15 a.m. – 9:35 a.m. ET
Location: Seaport Hotel & World Trade Center

Presentation Title: Improvement of Safety in T-cell Immunotherapies for the Treatment of Cancer
Session Title: Overcoming CAR-T Toxicity in Solid Tumors (Agenda 1)
Date & Time: Friday, September 7, 2018 from 1:00 p.m. – 1:30 p.m. ET
Location: Seaport Hotel & World Trade Center

On August 30, 2018 Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, reported that Derek Maetzold, President and CEO, will present at the Baird Global Healthcare Conference on Wednesday, September 5th, 2018 at 11:25 a.m. ET in New York City (Press release, Castle Biosciences, AUG 30, 2018, View Source [SID1234529198]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On August 30, 2018 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, reported that members of Rocket’s executive team will participate in the following upcoming investor conferences (Press release, Rocket Pharmaceuticals, AUG 30, 2018, View Source [SID1234529197]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 13th Annual Biotech Conference on September 6, 2018 in Boston, MA
Morgan Stanley 16th Annual Global Healthcare Conference on September 13, 2018 at 5:15 p.m. Eastern Time in New York, NY

A live audio webcast of the Morgan Stanley fireside chat will be available on the Investors section of the company’s website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

On August 21, 2018 Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing safe and more effective T cell therapies, reported that it will present data today on its novel T cell therapy technology, TAC-T, during an oral presentation in the Adoptive T Cell Therapies session of the 6th Annual Immuno-Oncology Summit held in Boston (Press release, Triumvira Immunologics, AUG 30, 2018, View Source [SID1234529196]). The presentation will describe the differentiated mechanism of action of the company’s T cell antigen coupler (TAC) technology in preclinical studies demonstrating strong efficacy in both solid and liquid tumors with an improved safety profile compared to traditional CAR-T approaches.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation, entitled: TAC-T: a novel T cell therapy, co-opts the endogenous T cell receptor for effective, safe, and persistent tumor rejection, will be delivered by Christopher Helsen, PhD, Director of Research and Development at Triumvira. Results from pre-clinical studies with human T cells engineered with Triumvira’s proprietary TAC technology directed against different antigens will be presented. The data suggest that TAC-T cells destroy tumor cells via a mechanism that mimics the natural process of T cell activation. Results clearly demonstrate efficient infiltration and proliferation in solid tumors resulting in rapid and sustained tumor regression in mice without toxicity. Furthermore, in a xenograft model of multiple myeloma, treated mice showed resistance to tumor re-challenge indicating long-term persistence of TAC-T cells.

"These results will further illustrate the potential of TAC-T cells, both in terms of efficacy and safety but also with respect to TAC T-cell persistence, a key point under consideration in T cell therapy," said Paul Lammers, MD, MSc, President and Chief Executive Officer.

Triumvira also announces it is participating in the 11th Annual International Partnering Conference BioPharm America on September 5-6 and the 4th Annual CAR-TCR Summit 2018 – Changing Lives with CAR-T & TCR Cell Immunotherapies on September 4-5, both being held during Biotech Week Boston. For more information, or to set up a meeting with Triumvira at either conference email: [email protected].

On August 30, 2018 vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, reported it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC (Press release, vTv Therapeutics, AUG 30, 2018, View Source [SID1234529195]).The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

vTv management will provide an overview of the company’s business during the live presentation at 1:45pm ET on September 6, 2018 in the Fontainebleau Foyer (2nd floor).

A live webcast of the presentation can be accessed here and will be archived for 30 days following the presentation at www.vtvtherapeutics.com.